Story · Medicine & Biotech
Neil Vasan Highlights the Accelerated FDA Approval of Daraxonrasib Through the Priority Voucher Program
1 outlet · first reported by OncoDaily on · latest · 25 hours of coverage
Neil Vasan, Director of Breast Cancer Translational Research at NYU Langone Health, shared on X: “PDAC patients and Revolution Medicines benefited uniquely from the priority voucher program. Daraxonrasib (RASONQUE) was (OncoDaily)
Coverage, in order
-
Neil Vasan Highlights the Accelerated FDA Approval of Daraxonrasib Through the Priority Voucher ProgramNeil Vasan, Director of Breast Cancer Translational Research at NYU Langone Health, shared on X: “PDAC patients and Revolution Medicines benefited uniquely from the priority voucher program. Daraxonrasib (RASONQUE) was
-
NEXT Oncology Highlights Its Impact in the Daraxonrasib Journey From Phase 1 to FDA ApprovalNEXT Oncology, an Avacare business shared on LinkedIn: “In 2022, NEXT Oncology treated one of the first patients with daraxonrasib, a potentially promising treatment for pancreatic cancer. Our sites went
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.